# Bioventus (BVS) — Earnings

BVS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bvs/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 27, 2026 |
| EPS actual | $0.22 |
| EPS estimate | $0.21 |
| EPS surprise | +2.95% |
| Revenue surprise | −1.10% |
| Revenue | $153.2M |
| Revenue estimate | $154.9M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1665988/000166598826000042/bvs-20260627.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/f9fa3367-39ed-0f3b-480a-b4d636d7c878.html) |

Bioventus reported Q2 2026 results on August 5, 2026. Earnings per share were $0.22, ahead of the $0.21 estimate by 2.95%. Revenue was $153.2 million, about 1.1% below the $154.9 million consensus. Compared with Q2 2025, EPS rose from $0.21 and revenue rose 3.7% from $147.7 million.

The table shows a recovery from weak results in 2022 and 2023. Annual EPS fell from $0.16 in 2022 to break-even in 2023, with losses in Q4 2022 and Q1 2023, the only losses in the table. It then rose to $0.47 in 2024 and $0.68 in 2025. The first half of 2026 adds up to $0.37, compared with $0.29 a year earlier. Annual revenue grew from $512.4 million in 2023 to about $568 million to $573 million in 2024 and 2025. Q4 2025 set the revenue high here at $157.9 million. Bioventus beat the EPS estimate in 15 of the last 20 quarters, including 13 in a row since Q2 2023.

Bioventus reported its third quarter between November 4 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether the run of EPS beats and year-over-year gains continues.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $0.21 | $0.22 | 2.95% | $154.9M | $153.2M |
| Q1 2026 | May 6, 2026 | $0.07 | $0.15 | 117.71% | $129.9M | $132.1M |
| Q4 2025 | Mar 5, 2026 | $0.22 | $0.24 | 11.21% | $154.9M | $157.9M |
| Q3 2025 | Nov 4, 2025 | $0.10 | $0.15 | 43.27% | $138.2M | $138.7M |
| Q2 2025 | Aug 6, 2025 | $0.16 | $0.21 | 33.67% | $145.9M | $147.7M |
| Q1 2025 | May 6, 2025 | $0.02 | $0.08 | 225.20% | $122.7M | $123.9M |
| Q4 2024 | Mar 11, 2025 | $0.08 | $0.15 | 81.60% | $145.2M | $153.6M |
| Q3 2024 | Nov 5, 2024 | $0.02 | $0.06 | 270.37% | $133.2M | $139.0M |
| Q2 2024 | Aug 6, 2024 | $0.07 | $0.19 | 182.74% | $137.6M | $151.2M |
| Q1 2024 | May 7, 2024 | −$0.07 | $0.07 | 204.95% | $118.4M | $129.5M |
| Q4 2023 | Mar 12, 2024 | $0.02 | $0.07 | 266.49% | $124.0M | $135.4M |
| Q3 2023 | Nov 7, 2023 | −$0.02 | $0.05 | 350.00% | $119.0M | $120.8M |
| Q2 2023 | Aug 8, 2023 | −$0.00 | $0.14 | 4342.42% | $129.2M | $137.1M |
| Q1 2023 | May 16, 2023 | −$0.15 | −$0.26 | -73.33% | $116.6M | $119.1M |
| Q4 2022 | Mar 31, 2023 | $0.05 | −$0.06 | -225.00% | $132.6M | $125.8M |
| Q3 2022 | Nov 8, 2022 | $0.12 | $0.08 | -34.91% | $141.6M | $137.1M |
| Q2 2022 | Aug 11, 2022 | $0.16 | $0.10 | -35.82% | $138.3M | $140.3M |
| Q1 2022 | May 10, 2022 | $0.05 | $0.04 | -16.14% | $117.7M | $117.3M |
| Q4 2021 | Mar 10, 2022 | $0.18 | $0.26 | 47.48% | $130.2M | $130.4M |
| Q3 2021 | Nov 9, 2021 | $0.14 | $0.25 | 77.94% | $102.4M | $108.9M |

## Frequently Asked Questions

### When did Bioventus (BVS) last report earnings?

Bioventus last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did BVS beat earnings estimates?

Yes. Bioventus reported EPS of $0.22 for Q2 2026 against a $0.21 estimate — a 2.95% beat.

### How much revenue did BVS report last quarter?

Bioventus reported $153.2M in revenue for Q2 2026, against a consensus estimate of $154.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).